Acute myeloid leukemia: trials for referral
835 open trials in the registries we read. Each row links to its registry record.
Registry data only. Frontlight does not judge whether a patient can take part: the trial team decides.
Acute myeloid leukemia·What we know·Glossary·Tumour board sheet
Where the open trials are
Type a city to sort by distance. The distance is worked out in your browser; the city is not sent anywhere.
400 trials shown · Showing the 400 most recently updated of 835 open trials.
Phase 21 site
RecruitingUnited States
NCT06930352
Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy
Uma Borate
Pre-treatment window Registry sentence: “Treatment-naïve acute myeloid leukemia”
Registry updated 9 Nov 2026
Registry record: ClinicalTrials.govNo phase1 site
RecruitingUnited States
NCT04986657
Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in AML and MDS
Washington University School of Medicine
Registry updated 9 Nov 2026
Registry record: ClinicalTrials.govPhase 21 site
RecruitingChina
NCT07925554
Interferon-α Maintenance in Favorable-Risk AML
Peking University People's Hospital
Registry updated 9 Nov 2026
Registry record: ClinicalTrials.govPhase 11 site
RecruitingGermany
NCT06252584
Multi-peptide Vaccination Adjuvanted With XS15 in Acute Myeloid Leukemia Patients
University Hospital Tuebingen
Registry updated 9 Nov 2026
Registry record: ClinicalTrials.govPhase 31 site
Not yet recruitingChina
NCT07925190
A Phase III Study Comparing Mesutoclax + Azacitidine Versus Venetoclax + Azacitidine in Untreated Acute Myeloid Leukemia (AML) Patients
Beijing InnoCare Pharma Tech Co., Ltd.
Registry updated 9 Nov 2026
Registry record: ClinicalTrials.govPhase 2227 sites
RecruitingCanada, Puerto Rico, United States
NCT05554406
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
National Cancer Institute (NCI)
Pre-treatment window Registry sentence: “Participants must have newly diagnosed, untreated acute myeloid leukemia (AML) per World Health Organization (WHO) criteria”
Registry updated 9 Nov 2026
Registry record: ClinicalTrials.govPhase 1/21 site
Not yet recruitingChina
NCT07926607
Palbociclib, All-Trans Retinoic Acid, and Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia
Second Affiliated Hospital of Nanchang University
Registry updated 9 Nov 2026
Registry record: ClinicalTrials.govPhase 11 site
RecruitingUnited States
NCT05672147
CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia
City of Hope Medical Center
Registry updated 9 Nov 2026
Registry record: ClinicalTrials.govPhase 11 site
RecruitingUnited States
NCT06996119
Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant
City of Hope Medical Center
Registry updated 9 Nov 2026
Registry record: ClinicalTrials.govPhase 17 sites
RecruitingUnited States
NCT07661095
A Study of CRD3874-SI in People With Leukemia
Memorial Sloan Kettering Cancer Center
Registry updated 9 Nov 2026
Registry record: ClinicalTrials.govPhase 1/22 sites
RecruitingUnited States
NCT05436418
The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation
National Cancer Institute (NCI)
Registry updated 6 Nov 2026
Registry record: ClinicalTrials.govPhase 11 site
Not yet recruitingUnited States
NCT07617363
ATRN-119 in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk MDS
Washington University School of Medicine
Registry updated 6 Nov 2026
Registry record: ClinicalTrials.govPhase 264 sites
RecruitingPuerto Rico, United States
NCT07437950
Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
National Cancer Institute (NCI)
Pre-treatment window Registry sentence: “Participants must have newly diagnosed, untreated acute myeloid leukemia (AML) defined by”
Registry updated 6 Nov 2026
Registry record: ClinicalTrials.govPhase 10 sites
Not yet recruiting
NCT07923071
A Study to Assess the Pharmacokinetics and Safety of Revumenib in Participants With Advanced Cancer and Hepatic or Renal Impairment
Syndax Pharmaceuticals
Registry updated 6 Nov 2026
Registry record: ClinicalTrials.govPhase 3175 sites
RecruitingAustria, Australia, Belgium, Switzerland, Germany, Denmark
NCT07223814
Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
Stichting Hemato-Oncologie voor Volwassenen Nederland
Registry updated 6 Nov 2026
Registry record: ClinicalTrials.govPhase 1/21 site
RecruitingUnited States
NCT04797767
Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
University of Washington
Registry updated 6 Nov 2026
Registry record: ClinicalTrials.govPhase 121 sites
RecruitingGermany, Spain, France, United Kingdom, Netherlands, Poland
NCT07751991
A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML
Charm Therapeutics
Registry updated 6 Nov 2026
Registry record: ClinicalTrials.govPhase 41 site
RecruitingUnited States
NCT06370000
Oral Azacitidine in Transplant-Eligible Patients With Acute Myeloid Leukemia (AML) Suffering From Health-Inequality
Virginia Commonwealth University
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govPhase 21 site
Not yet recruitingUnited States
NCT07605949
Revumenib, Azacitidine, and VENetoclax in Newly Diagnosed KMT2A-Rearranged AML
UNC Lineberger Comprehensive Cancer Center
Pre-treatment window Registry sentence: “Untreated AML based on 2022 WHO or ICC criteria with KMT2A translocation by local standard diagnostic testing by cytogenetics/karyotype or FISH”
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govPhase 142 sites
By invitation onlyAustralia, Belgium, Denmark, Spain, France, United Kingdom
NCT06788509
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
Janssen Research & Development, LLC
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 352 sites
RecruitingSpain
NCT07478991
Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI)
PETHEMA Foundation
Pre-treatment window Registry sentence: “The subject must have confirmation of AML by 2022 WHO criteria, previously untreated and be ineligible for treatment with a standard cytarabine and anthracycline based induction regimen due to age and/or comorbidities.”
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 21 site
RecruitingUnited States
NCT07471841
Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax
Timothy Pardee
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 2229 sites
RecruitingCanada, Puerto Rico, United States
NCT06317649
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
National Cancer Institute (NCI)
Pre-treatment window Registry sentence: “Patient must have no prior therapy for AML with the exception of hydroxyurea, all-trans retinoic acid (ATRA), cytarabine-based emergency therapy or leukapheresis to ensure white blood cells (WBC) \< 25,000/mm\^3 prior to starting venetoclax treatment”
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 281 sites
RecruitingPuerto Rico, United States
NCT06917911
Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)
National Cancer Institute (NCI)
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 19 sites
RecruitingDenmark, Spain, Italy
NCT07384715
First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS)
Genmab
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 11 site
RecruitingUnited States
NCT04716452
Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Keystone Nano, Inc
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govPhase 1/21 site
RecruitingUnited States
NCT06235801
A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govPhase 123 sites
RecruitingUnited States
NCT06484062
Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
National Cancer Institute (NCI)
Pre-treatment window Registry sentence: “In Cohort III, patients must have prior untreated high-risk MDS”
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govPhase 387 sites
RecruitingAustria, Belgium, Germany, Estonia, Finland, Lithuania
NCT04628026
Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2
University of Ulm
Pre-treatment window Registry sentence: “No prior chemotherapy for AML, except hydroxyurea for up to 14 days during the diagnostic screening phase for the control of peripheral leukemic blasts in patients with leukocytosis (e.g., white blood cell \[WBC\] counts \> 25x109/L); patients may have had previous treatment with erythroid stimulating agents (ESA) or hypomethylating agents (HMAs) for an antecedent phase of MDS; ESA and HMAs have to be stopped at least four weeks before start of study treatment.”
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govPhase 11 site
RecruitingUnited States
NCT02390752
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
National Cancer Institute (NCI)
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.gov
The same sites as a list
- United States238 open trials
- China87 open trials
- France35 open trials
- Spain33 open trials
- Italy28 open trials
- Germany24 open trials
- United Kingdom20 open trials
- Canada17 open trials
- Australia17 open trials
- Poland15 open trials
- Netherlands14 open trials
- Belgium11 open trials
- South Korea11 open trials
- Austria10 open trials
- Japan9 open trials
- Romania9 open trials
- Lithuania8 open trials
- Taiwan7 open trials
- Czechia7 open trials
- Israel6 open trials
- Hungary6 open trials
- Sweden5 open trials
- Denmark5 open trials
- Switzerland5 open trials
- Puerto Rico4 open trials
- Finland4 open trials
- Brazil4 open trials
- Portugal4 open trials
- Ireland3 open trials
- Estonia3 open trials
- Georgia3 open trials
- Greece3 open trials
- Norway3 open trials
- Armenia3 open trials
- Bulgaria3 open trials
- Slovakia3 open trials
- Ukraine2 open trials
- Argentina2 open trials
- Moldova1 open trial
- Mexico1 open trial
- Türkiye1 open trial
- Jordan1 open trial
- Philippines1 open trial
- Egypt1 open trial
- New Zealand1 open trial
- India1 open trial
- Russia1 open trial
- Uzbekistan1 open trial
- Pakistan1 open trial
- Hong Kong1 open trial
- Singapore1 open trial
Who treats this
Institutions with trials or publications in this disease (OpenAlex, registries). Institutions only, no people.
Cincinnati Children's Hospital Medical Center
Cincinnati, United States
22 trials · 88 publications · ROR
What changed in the last 7 days
Registry facts, one per line, newest first.
New in the registry
Interferon-α Maintenance in Favorable-Risk AML
NCT07925554 · Phase 2 · China
Source: ClinicalTrials.govOpened for recruitment
Multi-peptide Vaccination Adjuvanted With XS15 in Acute Myeloid Leukemia Patients
NCT06252584 · Phase 1 · Germany
Source: ClinicalTrials.govClosed for recruitment
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
NCT05183035 · Phase 3 · Austria, Australia, Belgium, Canada, Switzerland, Czechia
Source: ClinicalTrials.govPhase changed: Phase 1/2 → Phase 1
NCT06492304 · Phase 1 · Australia, United States
Source: ClinicalTrials.govOpened for recruitment
A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML
NCT07751991 · Phase 1 · Germany, Spain, France, United Kingdom, Netherlands, Poland
Source: ClinicalTrials.govPhase changed: Phase 1/2 → Phase 1
A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML
NCT07751991 · Phase 1 · Germany, Spain, France, United Kingdom, Netherlands, Poland
Source: ClinicalTrials.govStatus changed: Recruiting → By invitation only
Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical Trials
NCT07474051 · Phase 1 · Germany
Source: ClinicalTrials.govStatus changed: Recruiting → Not yet recruiting
NCT07214064 · Phase 2 · Germany
Source: ClinicalTrials.govStatus changed: Recruiting → Not yet recruiting
NCT07082452 · Phase 3 · Spain, France
Source: ClinicalTrials.govStatus changed: Recruiting → By invitation only
NCT06987058 · Phase 2 · Spain, France, Italy, Poland
Source: ClinicalTrials.govOpened for recruitment
Anti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical Transplantation
NCT06892223 · Phase 2 · Italy
Source: ClinicalTrials.govOpened for recruitment
Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
NCT06846606 · Phase 1 · France, United States
Source: ClinicalTrials.govPhase changed: Phase 2/3 → Phase 2
Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia
NCT06668558 · Phase 2 · Spain
Source: ClinicalTrials.govStatus changed: Recruiting → Not yet recruiting
NCT06667973 · Phase 2 · Italy
Source: ClinicalTrials.govClosed for recruitment
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
NCT06578247 · Phase 3 · Austria, Australia, Belgium, Bulgaria, Brazil, Canada
Source: ClinicalTrials.gov
Show more
Status changed: Recruiting → Not yet recruiting
NCT06602323 · Phase 2 · Spain
Source: ClinicalTrials.govPhase changed: Phase 1/2 → Phase 1
NCT06533761 · Phase 1 · Spain, United States
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
NCT06359002 · Phase 1 · Belgium, Spain, Netherlands
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
NCT05833438 · Phase 2 · Germany
Source: ClinicalTrials.govPhase changed: Phase 1/2 → Phase 1
Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome
NCT05673057 · Phase 1 · Switzerland, France, Lithuania, Netherlands
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
NCT05428969 · Phase 1/2 · Finland, United Kingdom, United States
Source: ClinicalTrials.govOpened for recruitment
NCT04953910 · Phase 1 · Armenia, Bulgaria, Spain, Lithuania, Poland, Romania
Source: ClinicalTrials.govOpened for recruitment
Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia
NCT04793919 · Phase 2 · Belgium, Czechia, Germany, Denmark, Spain, France
Source: ClinicalTrials.govPhase changed: Phase 2 → Phase 1/2
NCT04657081 · Phase 1/2 · Canada, Spain, United States
Source: ClinicalTrials.govPhase changed: Phase 3 → Phase 2/3
NCT04256317 · Phase 2/3 · Canada, Czechia, Germany, Spain, France, United Kingdom
Source: ClinicalTrials.govOpened for recruitment
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)
NCT04093570 · Phase 2 · Armenia, Austria, Bulgaria, Canada, Germany, Spain
Source: ClinicalTrials.govPhase changed: Phase 2 → Phase 3
NCT04027309 · Phase 3 · Austria, Australia, Belgium, Switzerland, Germany, Spain
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
NCT04023526 · Phase 2 · Australia, Brazil, Switzerland, Spain, France, Israel
Source: ClinicalTrials.govClosed for recruitment
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
NCT04067336 · Phase 1/2 · Belgium, Canada, Germany, Spain, France, Italy
Source: ClinicalTrials.govOpened for recruitment
NCT03850574 · Phase 1/2 · Australia, Germany, Spain, South Korea, New Zealand, Poland
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN
NCT03386513 · Phase 1/2 · Germany, Spain, France, United Kingdom, Italy, United States
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
NCT02993523 · Phase 3 · Austria, Australia, Belgium, Brazil, Canada, China
Source: ClinicalTrials.govClosed for recruitment
NCT04953910 · Phase 1 · Armenia, Bulgaria, Spain, Lithuania, Poland, Romania
Source: ClinicalTrials.govClosed for recruitment
Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia
NCT04793919 · Phase 2 · Belgium, Czechia, Germany, Denmark, Spain, France
Source: ClinicalTrials.govClosed for recruitment
NCT03850574 · Phase 1/2 · Australia, Germany, Spain, South Korea, New Zealand, Poland
Source: ClinicalTrials.govClosed for recruitment
Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
NCT06846606 · Phase 1 · France, United States
Source: ClinicalTrials.govStatus changed: Recruiting → Not yet recruiting
NCT05506332 · Phase 1 · Belgium
Source: ClinicalTrials.govOpened for recruitment
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
NCT04067336 · Phase 1/2 · Belgium, Canada, Germany, Spain, France, Italy
Source: ClinicalTrials.govClosed for recruitment
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)
NCT04093570 · Phase 2 · Armenia, Austria, Bulgaria, Canada, Germany, Spain
Source: ClinicalTrials.govClosed for recruitment
Anti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical Transplantation
NCT06892223 · Phase 2 · Italy
Source: ClinicalTrials.govOpened for recruitment
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
NCT06578247 · Phase 3 · Austria, Australia, Belgium, Bulgaria, Brazil, Canada
Source: ClinicalTrials.govStatus changed: Recruiting → Not yet recruiting
A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML
NCT07751991 · Phase 1 · Germany, Spain, France, United Kingdom, Netherlands, Poland
Source: ClinicalTrials.govStopped early
Hu8F4 in Treating Patients With Advanced Hematologic Malignancies
NCT02530034 · Phase 1 · United States
Source: ClinicalTrials.govPhase changed: No phase → Phase 4
PTX3-targeted Antifungal Prophylaxis
NCT03828773 · Phase 4 · Belgium, Switzerland, France
Source: ClinicalTrials.govPhase changed: No phase → Phase 1
Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical Trials
NCT07474051 · Phase 1 · Germany
Source: ClinicalTrials.gov
New reviews, guidelines and randomised trials in PubMed
Meta-analysis
Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · PubMed
Results card
Trials that finished or stopped in the last 3 years, with the reason the registry gives and linked publications.
No phaseEnded 1 Nov 2026
Withdrawn before start0 participants
NCT06116318
A Study of c-Kit Mutation as MRD in Acute Myeloid Leukemia
Reason given: The test for c-kit was not set up and replaced by NGS MRD
Phase 1Ended 22 Oct 2026
Completed24 participants
2023-505828-58-00
CA-4948-104: A Ph1 Study of Emavusertib in AML CR MRD+ Patients Currently Receiving Azacitidine and Venetoclax
Phase 1Ended 15 Oct 2026
Stopped early15 participants
NCT02530034
Hu8F4 in Treating Patients With Advanced Hematologic Malignancies
Reason given: FDA Clinical Hold
Phase 2Ended 12 Oct 2026
Stopped early36 participants
NCT04062266
AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission
Reason given: \<75% participation
No phaseEnded 30 Sept 2026
Completed307 participants
NCT04635384
Assessment of Chimerism and Relapse Post Bone Marrow/Hematopoietic Cell Transplant (HCT) Using AlloHeme Test
Phase 1Ended 16 Sept 2026
Stopped early52 participants
NCT06714591
Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1
Reason given: Sponsor prioritization of other development portfolio
Phase 1Ended 14 Sept 2026
Completed80 participants
NCT05673057
Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase 1/2Ended 8 Sept 2026
Stopped early2 participants
NCT06704152
BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS
Reason given: Company Decision
Phase 1Ended 8 Sept 2026
Withdrawn before start0 participants
NCT07566585
Dose Finding Study to Evaluate the Safety of BSB-2002 in Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients With NPM1 Mutation
Reason given: Company Decision
Phase 2Ended 8 Sept 2026
Completed93 participants
NCT04233346
The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation
Phase 1Ended 1 Sept 2026
Completed64 participants
NCT06618001
A Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms
No phaseEnded 31 Aug 2026
Stopped early210 participants
NCT05424562
A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada
Reason given: Strategic Considerations
Phase 1Ended 28 Aug 2026
Stopped early34 participants
NCT06419634
Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Reason given: Inability to meet protocol objectives
Phase 1Ended 17 Aug 2026
Paused24 participants
NCT06709131
A Clinical Study to Explore the Safety and Efficacy of CT0991 in Relapsed/Refractory Acute Myeloid Leukemia
Reason given: Product manufacturing process improvement
No phaseEnded 15 Aug 2026
Completed22 participants
NCT07062250
Feasibility and Safety of Home Blood Count Measurement and Transfusions in Patients With Acute Myeloid Leukemia
Phase 1/2Ended 14 Aug 2026
Stopped early58 participants
NCT02392572
ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome
Reason given: \<75% participants
Phase 1Ended 6 Aug 2026
Completed35 participants
2024-519537-29-00
A Phase I Study of BMS-986497 alone or in combination with Azacitidine (Aza) and Azacitidine plus Venetoclax (AZA+VEN) in relapsed or refractory (R/R) AML or MDS
Phase 1Ended 3 Aug 2026
Withdrawn before start0 participants
NCT05720988
Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid Leukemia
Reason given: trial was not opened
No phaseEnded Jul 2026
Completed400 participants
NCT02938858
French Registry of First-line Treatment of Acute Promyelocytic Leukemia
Phase 1/2Ended 31 Jul 2026
Stopped early10 participants
NCT04010877
Multiple CAR-T Cell Therapy Targeting AML
No reason given in the registry.
Show more
Phase 3Ended 29 Jul 2026
Phase 1Ended 21 Jul 2026
Completed6 participants
NCT07295951
A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia
No phaseEnded 21 Jul 2026
Phase 2Ended 17 Jul 2026
Phase 2Ended 16 Jul 2026
Stopped early23 participants
NCT04994808
Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid Leukemia
Reason given: The study was closed due to the end of funding.
Phase 2Ended 15 Jul 2026
Completed124 participants
NCT03455504
Venetoclax Add in Combination With Fludarabine, Cyratabine and Idarubicine in Induction for Acute Myelid Leukemia
No phaseEnded 15 Jul 2026
Phase 1/2Ended Jun 2026
Completed33 participants
NCT02204085
A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1Ended Jun 2026
Completed30 participants
NCT02494167
Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM)
Phase 2Ended 30 Jun 2026
Completed181 participants
NCT03836209
Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia
No phaseEnded 10 Jun 2026
Phase 2Ended 2 Jun 2026
Phase 1Ended 2 Jun 2026
Stopped early2 participants
NCT06158100
Venetoclax in Combination With Azacitidine (VEN/AZA) Followed by Donor Lymphocyte Infusion (DLI) for Patients With Very High-Risk Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)
Reason given: Funding Sponsor decision due to review of efficacy data from other trials involving investigational product.
Phase 1Ended 1 Jun 2026
Withdrawn before start0 participants
NCT03939585
Preemptive Infusion of Donor Lymphocytes Depleted of TCR + T Cells + CD19+ B Cells Following ASCT
Reason given: Lack of funding
No phaseEnded 29 May 2026
Phase 2Ended 27 May 2026
No phaseEnded 26 May 2026
Phase 2Ended 20 May 2026
Completed60 participants
NCT04195945
CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients
No phaseEnded 15 May 2026
No phaseEnded 14 May 2026
Stopped early200 participants
NCT01962636
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
Reason given: No longer a research question to answer.
Phase 1Ended 8 May 2026
Completed6 participants
NCT05564650
Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome
Phase 1Ended 30 Apr 2026
Phase 3Ended 30 Apr 2026
Phase 3Ended 29 Apr 2026
Completed326 participants
NCT04173533
Randomised Study of Oral Azacitidine vs Placebo Maintenance in AML or MDS Patients After Allo-SCT
Phase 2Ended 16 Apr 2026
Completed21 participants
NCT04269213
CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old
Phase 1Ended 15 Apr 2026
Completed134 participants
NCT02942290
A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)
Phase 3Ended 6 Apr 2026
Completed214 participants
NCT03258931
Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML
Phase 3Ended 3 Apr 2026
Completed106 participants
NCT03250338
Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML
Phase 3Ended 31 Mar 2026
Completed1645 participants
NCT01371981
Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase 1/2Ended 30 Mar 2026
Early Phase 1Ended 30 Mar 2026
Withdrawn before start0 participants
NCT07338357
Clinical Study of CLL-1 CAR-T in the Treatment of Children With R/R AML
Reason given: Strategic adjustment.
Phase 1/2Ended 27 Mar 2026
Completed57 participants
NCT04742101
Phase I/II Trial of S65487 Plus Azacitidine in Acute Myeloid Leukemia
Phase 1Ended 24 Mar 2026
Stopped early3 participants
NCT06021600
A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous Cladribine
Reason given: Slow participant enrollment
Phase 1Ended 19 Mar 2026
Completed12 participants
NCT03009240
Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia
Phase 1Ended 19 Mar 2026
Completed3 participants
NCT05441514
Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Phase 1Ended 11 Mar 2026
Completed12 participants
NCT06492304
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies
Phase 2Ended 5 Mar 2026
Stopped early235 participants
NCT03404193
Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome
Reason given: \<75% participation
Phase 1Ended 5 Mar 2026
Stopped early22 participants
NCT03766126
Lentivirally Redirected CD123 Autologous T Cells in AML
Reason given: Administrative reasons.
Phase 3Ended 28 Feb 2026
Completed60 participants
NCT05654194
Azacitidine Combined With Venetoclax and ATRA in Newly Diagnosed AML
No phaseEnded 28 Feb 2026
Completed44 participants
NCT07458542
Effectiveness and Safety of ONUREG (Oral Azacitidine) in Chinese Patients With Acute Myeloid Leukemia
Not medical advice. fetched 10 Nov 2026